Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 523,684
  • Shares Outstanding, K 73,448
  • Annual Sales, $ 143,010 K
  • Annual Income, $ -400,420 K
  • 60-Month Beta 3.12
  • Price/Sales 2.77
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -1.27
  • Number of Estimates 5
  • High Estimate -1.22
  • Low Estimate -1.33
  • Prior Year -1.63
  • Growth Rate Est. (year over year) +22.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.62 +89.23%
on 03/17/20
8.74 -21.62%
on 03/05/20
-0.68 (-9.03%)
since 02/28/20
3-Month
3.62 +89.23%
on 03/17/20
11.63 -41.10%
on 02/20/20
-4.30 (-38.57%)
since 12/27/19
52-Week
2.93 +133.79%
on 10/28/19
25.88 -73.53%
on 04/08/19
-17.97 (-72.40%)
since 03/29/19

Most Recent Stories

More News
Why Is Clovis (CLVS) Down 41.6% Since Last Earnings Report?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CLVS : 6.90 (-3.23%)
Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

CLVS : 6.90 (-3.23%)
Clovis Oncology (CLVS) Gains But Lags Market: What You Should Know

Clovis Oncology (CLVS) closed the most recent trading day at $4.50, moving +0.45% from the previous trading session.

CLVS : 6.90 (-3.23%)
After Yesterday's Decline of 7.29%, Clovis Oncology Offers Investors Better Value

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $4.40 to a high of $5.64. Yesterday, the shares fell 7.3%, which took the trading range below the 3-day low of $4.91...

CLVS : 6.90 (-3.23%)
Non-Opioid Pain Relief Progress Showing Impressive Growth Rate Opportunities

Opioid drugs are and have been a God-send for many patients whose severe, excruciating pain had no other drug or device to allow them to escape from its throes. But we all know that the other side of that...

QBIO : 1.5499 (-0.01%)
CLVS : 6.90 (-3.23%)
VBIV : 0.9415 (+1.18%)
OPK : 1.3650 (-2.50%)
MNK : 2.42 (+8.52%)
Clovis Oncology (CLVS) Stock Moves -1.59%: What You Should Know

Clovis Oncology (CLVS) closed the most recent trading day at $6.17, moving -1.59% from the previous trading session.

CLVS : 6.90 (-3.23%)
Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance

FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.

HALO : 18.05 (+3.14%)
CHRS : 16.39 (+0.80%)
CLVS : 6.90 (-3.23%)
TRVN : 0.5836 (+1.92%)
Clovis Oncology Rises 5.75% on Heavy Volume: Watch For Potential Pullback

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $7.78 to a high of $8.74. Yesterday, the shares gained 5.7%, which took the trading range above the 3-day high of...

CLVS : 6.90 (-3.23%)
How to Find Strong Cheap Stocks to Buy Under $10 Despite Coronavirus Fears

How to Find Strong Cheap Stocks to Buy Under $10 Despite Coronavirus Fears

SPWR : 5.32 (-2.74%)
MSFT : 157.80 (+5.41%)
MA : 246.80 (-0.34%)
KGC : 4.46 (+5.69%)
GGB : 1.88 (-6.00%)
CLVS : 6.90 (-3.23%)
AMCR : 8.13 (+4.23%)
AAPL : 251.75 (+1.62%)
Clovis Oncology to Present at the Barclays Global Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Barclays Global Healthcare Conference on Tuesday, March 10,...

CLVS : 6.90 (-3.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade CLVS with:

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

2nd Resistance Point 9.21
1st Resistance Point 8.17
Last Price 6.90
1st Support Level 5.62
2nd Support Level 4.11

See More

52-Week High 25.88
Fibonacci 61.8% 17.11
Fibonacci 50% 14.40
Fibonacci 38.2% 11.70
Last Price 6.90
52-Week Low 2.93

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar